Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
33,560
archived clinical trials in
Neurology

Study to Assess the Safety and Tolerability of Intravenous Carbamazepine in Adults With Epilepsy
Open-Label Study to Assess the Safety and Tolerability of Intravenous Carbamazepine as Short-Term Replacement of Oral Carbamazepine in Adult Patients With Epilepsy
Status: Enrolling
Updated:  12/14/2017
Cleveland Clinic
mi
from
Cleveland, OH
Study to Assess the Safety and Tolerability of Intravenous Carbamazepine in Adults With Epilepsy
Open-Label Study to Assess the Safety and Tolerability of Intravenous Carbamazepine as Short-Term Replacement of Oral Carbamazepine in Adult Patients With Epilepsy
Status: Enrolling
Updated: 12/14/2017
Cleveland Clinic
mi
from
Cleveland, OH
Click here to add this to my saved trials
Study to Assess the Safety and Tolerability of Intravenous Carbamazepine in Adults With Epilepsy
Open-Label Study to Assess the Safety and Tolerability of Intravenous Carbamazepine as Short-Term Replacement of Oral Carbamazepine in Adult Patients With Epilepsy
Status: Enrolling
Updated:  12/14/2017
Temple University Health systems
mi
from
Philadelphia, PA
Study to Assess the Safety and Tolerability of Intravenous Carbamazepine in Adults With Epilepsy
Open-Label Study to Assess the Safety and Tolerability of Intravenous Carbamazepine as Short-Term Replacement of Oral Carbamazepine in Adult Patients With Epilepsy
Status: Enrolling
Updated: 12/14/2017
Temple University Health systems
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Study to Assess the Safety and Tolerability of Intravenous Carbamazepine in Adults With Epilepsy
Open-Label Study to Assess the Safety and Tolerability of Intravenous Carbamazepine as Short-Term Replacement of Oral Carbamazepine in Adult Patients With Epilepsy
Status: Enrolling
Updated:  12/14/2017
Medical University of South Carolina
mi
from
Charleston, SC
Study to Assess the Safety and Tolerability of Intravenous Carbamazepine in Adults With Epilepsy
Open-Label Study to Assess the Safety and Tolerability of Intravenous Carbamazepine as Short-Term Replacement of Oral Carbamazepine in Adult Patients With Epilepsy
Status: Enrolling
Updated: 12/14/2017
Medical University of South Carolina
mi
from
Charleston, SC
Click here to add this to my saved trials
Study to Assess the Safety and Tolerability of Intravenous Carbamazepine in Adults With Epilepsy
Open-Label Study to Assess the Safety and Tolerability of Intravenous Carbamazepine as Short-Term Replacement of Oral Carbamazepine in Adult Patients With Epilepsy
Status: Enrolling
Updated:  12/14/2017
Neurological Clinic - Texas
mi
from
Dallas, TX
Study to Assess the Safety and Tolerability of Intravenous Carbamazepine in Adults With Epilepsy
Open-Label Study to Assess the Safety and Tolerability of Intravenous Carbamazepine as Short-Term Replacement of Oral Carbamazepine in Adult Patients With Epilepsy
Status: Enrolling
Updated: 12/14/2017
Neurological Clinic - Texas
mi
from
Dallas, TX
Click here to add this to my saved trials
Study to Assess the Safety and Tolerability of Intravenous Carbamazepine in Adults With Epilepsy
Open-Label Study to Assess the Safety and Tolerability of Intravenous Carbamazepine as Short-Term Replacement of Oral Carbamazepine in Adult Patients With Epilepsy
Status: Enrolling
Updated:  12/14/2017
Scott & White Memorial Hospital
mi
from
Temple, TX
Study to Assess the Safety and Tolerability of Intravenous Carbamazepine in Adults With Epilepsy
Open-Label Study to Assess the Safety and Tolerability of Intravenous Carbamazepine as Short-Term Replacement of Oral Carbamazepine in Adult Patients With Epilepsy
Status: Enrolling
Updated: 12/14/2017
Scott & White Memorial Hospital
mi
from
Temple, TX
Click here to add this to my saved trials
Study to Assess the Safety and Tolerability of Intravenous Carbamazepine in Adults With Epilepsy
Open-Label Study to Assess the Safety and Tolerability of Intravenous Carbamazepine as Short-Term Replacement of Oral Carbamazepine in Adult Patients With Epilepsy
Status: Enrolling
Updated:  12/14/2017
University of Virginia
mi
from
Charlottesville, VA
Study to Assess the Safety and Tolerability of Intravenous Carbamazepine in Adults With Epilepsy
Open-Label Study to Assess the Safety and Tolerability of Intravenous Carbamazepine as Short-Term Replacement of Oral Carbamazepine in Adult Patients With Epilepsy
Status: Enrolling
Updated: 12/14/2017
University of Virginia
mi
from
Charlottesville, VA
Click here to add this to my saved trials
Study to Assess the Safety and Tolerability of Intravenous Carbamazepine in Adults With Epilepsy
Open-Label Study to Assess the Safety and Tolerability of Intravenous Carbamazepine as Short-Term Replacement of Oral Carbamazepine in Adult Patients With Epilepsy
Status: Enrolling
Updated:  12/14/2017
Mayo Clinic
mi
from
Phoenix, AZ
Study to Assess the Safety and Tolerability of Intravenous Carbamazepine in Adults With Epilepsy
Open-Label Study to Assess the Safety and Tolerability of Intravenous Carbamazepine as Short-Term Replacement of Oral Carbamazepine in Adult Patients With Epilepsy
Status: Enrolling
Updated: 12/14/2017
Mayo Clinic
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Study to Assess the Safety and Tolerability of Intravenous Carbamazepine in Adults With Epilepsy
Open-Label Study to Assess the Safety and Tolerability of Intravenous Carbamazepine as Short-Term Replacement of Oral Carbamazepine in Adult Patients With Epilepsy
Status: Enrolling
Updated:  12/14/2017
Collaborative Neuroscience Network, INC
mi
from
Torrance, CA
Study to Assess the Safety and Tolerability of Intravenous Carbamazepine in Adults With Epilepsy
Open-Label Study to Assess the Safety and Tolerability of Intravenous Carbamazepine as Short-Term Replacement of Oral Carbamazepine in Adult Patients With Epilepsy
Status: Enrolling
Updated: 12/14/2017
Collaborative Neuroscience Network, INC
mi
from
Torrance, CA
Click here to add this to my saved trials
Study to Assess the Safety and Tolerability of Intravenous Carbamazepine in Adults With Epilepsy
Open-Label Study to Assess the Safety and Tolerability of Intravenous Carbamazepine as Short-Term Replacement of Oral Carbamazepine in Adult Patients With Epilepsy
Status: Enrolling
Updated:  12/14/2017
Ochsner Clinic Foundation
mi
from
New Orleans, LA
Study to Assess the Safety and Tolerability of Intravenous Carbamazepine in Adults With Epilepsy
Open-Label Study to Assess the Safety and Tolerability of Intravenous Carbamazepine as Short-Term Replacement of Oral Carbamazepine in Adult Patients With Epilepsy
Status: Enrolling
Updated: 12/14/2017
Ochsner Clinic Foundation
mi
from
New Orleans, LA
Click here to add this to my saved trials
Study to Assess the Safety and Tolerability of Intravenous Carbamazepine in Adults With Epilepsy
Open-Label Study to Assess the Safety and Tolerability of Intravenous Carbamazepine as Short-Term Replacement of Oral Carbamazepine in Adult Patients With Epilepsy
Status: Enrolling
Updated:  12/14/2017
University of Minnesota & Prism Research
mi
from
Saint Paul, MN
Study to Assess the Safety and Tolerability of Intravenous Carbamazepine in Adults With Epilepsy
Open-Label Study to Assess the Safety and Tolerability of Intravenous Carbamazepine as Short-Term Replacement of Oral Carbamazepine in Adult Patients With Epilepsy
Status: Enrolling
Updated: 12/14/2017
University of Minnesota & Prism Research
mi
from
Saint Paul, MN
Click here to add this to my saved trials
Study to Assess the Safety and Tolerability of Intravenous Carbamazepine in Adults With Epilepsy
Open-Label Study to Assess the Safety and Tolerability of Intravenous Carbamazepine as Short-Term Replacement of Oral Carbamazepine in Adult Patients With Epilepsy
Status: Enrolling
Updated:  12/14/2017
SUNY Upstate Medical University
mi
from
Syracuse, NY
Study to Assess the Safety and Tolerability of Intravenous Carbamazepine in Adults With Epilepsy
Open-Label Study to Assess the Safety and Tolerability of Intravenous Carbamazepine as Short-Term Replacement of Oral Carbamazepine in Adult Patients With Epilepsy
Status: Enrolling
Updated: 12/14/2017
SUNY Upstate Medical University
mi
from
Syracuse, NY
Click here to add this to my saved trials
Study to Assess the Safety and Tolerability of Intravenous Carbamazepine in Adults With Epilepsy
Open-Label Study to Assess the Safety and Tolerability of Intravenous Carbamazepine as Short-Term Replacement of Oral Carbamazepine in Adult Patients With Epilepsy
Status: Enrolling
Updated:  12/14/2017
VCU Medical Center
mi
from
Richmond, VA
Study to Assess the Safety and Tolerability of Intravenous Carbamazepine in Adults With Epilepsy
Open-Label Study to Assess the Safety and Tolerability of Intravenous Carbamazepine as Short-Term Replacement of Oral Carbamazepine in Adult Patients With Epilepsy
Status: Enrolling
Updated: 12/14/2017
VCU Medical Center
mi
from
Richmond, VA
Click here to add this to my saved trials
Vagus Nerve Stimulation Clinical Outcomes Measured Prospectively in Patients Stimulated
A Post Market, Long Term, Prospective, Observational, Multi-site Outcome Study to Follow the Clinical Course and Seizure Reduction of Patients With Refractory Seizures Who Are Being Treated With Adjunctive VNS Therapy.
Status: Enrolling
Updated:  12/14/2017
Emory Healthcare
mi
from
Atlanta, GA
Vagus Nerve Stimulation Clinical Outcomes Measured Prospectively in Patients Stimulated
A Post Market, Long Term, Prospective, Observational, Multi-site Outcome Study to Follow the Clinical Course and Seizure Reduction of Patients With Refractory Seizures Who Are Being Treated With Adjunctive VNS Therapy.
Status: Enrolling
Updated: 12/14/2017
Emory Healthcare
mi
from
Atlanta, GA
Click here to add this to my saved trials
Vagus Nerve Stimulation Clinical Outcomes Measured Prospectively in Patients Stimulated
A Post Market, Long Term, Prospective, Observational, Multi-site Outcome Study to Follow the Clinical Course and Seizure Reduction of Patients With Refractory Seizures Who Are Being Treated With Adjunctive VNS Therapy.
Status: Enrolling
Updated:  12/14/2017
University of Illinois College of Medicine at Peoria
mi
from
Peoria, IL
Vagus Nerve Stimulation Clinical Outcomes Measured Prospectively in Patients Stimulated
A Post Market, Long Term, Prospective, Observational, Multi-site Outcome Study to Follow the Clinical Course and Seizure Reduction of Patients With Refractory Seizures Who Are Being Treated With Adjunctive VNS Therapy.
Status: Enrolling
Updated: 12/14/2017
University of Illinois College of Medicine at Peoria
mi
from
Peoria, IL
Click here to add this to my saved trials
Vagus Nerve Stimulation Clinical Outcomes Measured Prospectively in Patients Stimulated
A Post Market, Long Term, Prospective, Observational, Multi-site Outcome Study to Follow the Clinical Course and Seizure Reduction of Patients With Refractory Seizures Who Are Being Treated With Adjunctive VNS Therapy.
Status: Enrolling
Updated:  12/14/2017
University of Louisville Hospital
mi
from
Louisville, KY
Vagus Nerve Stimulation Clinical Outcomes Measured Prospectively in Patients Stimulated
A Post Market, Long Term, Prospective, Observational, Multi-site Outcome Study to Follow the Clinical Course and Seizure Reduction of Patients With Refractory Seizures Who Are Being Treated With Adjunctive VNS Therapy.
Status: Enrolling
Updated: 12/14/2017
University of Louisville Hospital
mi
from
Louisville, KY
Click here to add this to my saved trials
Vagus Nerve Stimulation Clinical Outcomes Measured Prospectively in Patients Stimulated
A Post Market, Long Term, Prospective, Observational, Multi-site Outcome Study to Follow the Clinical Course and Seizure Reduction of Patients With Refractory Seizures Who Are Being Treated With Adjunctive VNS Therapy.
Status: Enrolling
Updated:  12/14/2017
Cornell University
mi
from
New York, NY
Vagus Nerve Stimulation Clinical Outcomes Measured Prospectively in Patients Stimulated
A Post Market, Long Term, Prospective, Observational, Multi-site Outcome Study to Follow the Clinical Course and Seizure Reduction of Patients With Refractory Seizures Who Are Being Treated With Adjunctive VNS Therapy.
Status: Enrolling
Updated: 12/14/2017
Cornell University
mi
from
New York, NY
Click here to add this to my saved trials
Vagus Nerve Stimulation Clinical Outcomes Measured Prospectively in Patients Stimulated
A Post Market, Long Term, Prospective, Observational, Multi-site Outcome Study to Follow the Clinical Course and Seizure Reduction of Patients With Refractory Seizures Who Are Being Treated With Adjunctive VNS Therapy.
Status: Enrolling
Updated:  12/14/2017
Vanderbilt University Medical Center
mi
from
Nashville, TN
Vagus Nerve Stimulation Clinical Outcomes Measured Prospectively in Patients Stimulated
A Post Market, Long Term, Prospective, Observational, Multi-site Outcome Study to Follow the Clinical Course and Seizure Reduction of Patients With Refractory Seizures Who Are Being Treated With Adjunctive VNS Therapy.
Status: Enrolling
Updated: 12/14/2017
Vanderbilt University Medical Center
mi
from
Nashville, TN
Click here to add this to my saved trials
Vagus Nerve Stimulation Clinical Outcomes Measured Prospectively in Patients Stimulated
A Post Market, Long Term, Prospective, Observational, Multi-site Outcome Study to Follow the Clinical Course and Seizure Reduction of Patients With Refractory Seizures Who Are Being Treated With Adjunctive VNS Therapy.
Status: Enrolling
Updated:  12/14/2017
Covenant Hospital
mi
from
Lubbock, TX
Vagus Nerve Stimulation Clinical Outcomes Measured Prospectively in Patients Stimulated
A Post Market, Long Term, Prospective, Observational, Multi-site Outcome Study to Follow the Clinical Course and Seizure Reduction of Patients With Refractory Seizures Who Are Being Treated With Adjunctive VNS Therapy.
Status: Enrolling
Updated: 12/14/2017
Covenant Hospital
mi
from
Lubbock, TX
Click here to add this to my saved trials
Vagus Nerve Stimulation Clinical Outcomes Measured Prospectively in Patients Stimulated
A Post Market, Long Term, Prospective, Observational, Multi-site Outcome Study to Follow the Clinical Course and Seizure Reduction of Patients With Refractory Seizures Who Are Being Treated With Adjunctive VNS Therapy.
Status: Enrolling
Updated:  12/14/2017
St. Luke's Milwaukee
mi
from
Milwaukee, WI
Vagus Nerve Stimulation Clinical Outcomes Measured Prospectively in Patients Stimulated
A Post Market, Long Term, Prospective, Observational, Multi-site Outcome Study to Follow the Clinical Course and Seizure Reduction of Patients With Refractory Seizures Who Are Being Treated With Adjunctive VNS Therapy.
Status: Enrolling
Updated: 12/14/2017
St. Luke's Milwaukee
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Vagus Nerve Stimulation Clinical Outcomes Measured Prospectively in Patients Stimulated
A Post Market, Long Term, Prospective, Observational, Multi-site Outcome Study to Follow the Clinical Course and Seizure Reduction of Patients With Refractory Seizures Who Are Being Treated With Adjunctive VNS Therapy.
Status: Enrolling
Updated:  12/14/2017
UZ Gasthuisberg
mi
from
Leuven,
Vagus Nerve Stimulation Clinical Outcomes Measured Prospectively in Patients Stimulated
A Post Market, Long Term, Prospective, Observational, Multi-site Outcome Study to Follow the Clinical Course and Seizure Reduction of Patients With Refractory Seizures Who Are Being Treated With Adjunctive VNS Therapy.
Status: Enrolling
Updated: 12/14/2017
UZ Gasthuisberg
mi
from
Leuven,
Click here to add this to my saved trials
Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease Modifying Therapy in Patients With Relapsing Remitting Multiple Sclerosis.
A 12-month, Prospective, Randomized, Active-controlled, Open-label Study to Evaluate the Patient Retention of Fingolimod vs. Approved First-line Disease Modifying Therapies in Adults With Relapsing Remitting Multiple Sclerosis (PREFERMS)
Status: Enrolling
Updated:  12/14/2017
Novartis Investigative Site
mi
from
Cullman, AL
Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease Modifying Therapy in Patients With Relapsing Remitting Multiple Sclerosis.
A 12-month, Prospective, Randomized, Active-controlled, Open-label Study to Evaluate the Patient Retention of Fingolimod vs. Approved First-line Disease Modifying Therapies in Adults With Relapsing Remitting Multiple Sclerosis (PREFERMS)
Status: Enrolling
Updated: 12/14/2017
Novartis Investigative Site
mi
from
Cullman, AL
Click here to add this to my saved trials
Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease Modifying Therapy in Patients With Relapsing Remitting Multiple Sclerosis.
A 12-month, Prospective, Randomized, Active-controlled, Open-label Study to Evaluate the Patient Retention of Fingolimod vs. Approved First-line Disease Modifying Therapies in Adults With Relapsing Remitting Multiple Sclerosis (PREFERMS)
Status: Enrolling
Updated:  12/14/2017
Novartis Investigative Site
mi
from
Phoenix, AZ
Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease Modifying Therapy in Patients With Relapsing Remitting Multiple Sclerosis.
A 12-month, Prospective, Randomized, Active-controlled, Open-label Study to Evaluate the Patient Retention of Fingolimod vs. Approved First-line Disease Modifying Therapies in Adults With Relapsing Remitting Multiple Sclerosis (PREFERMS)
Status: Enrolling
Updated: 12/14/2017
Novartis Investigative Site
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease Modifying Therapy in Patients With Relapsing Remitting Multiple Sclerosis.
A 12-month, Prospective, Randomized, Active-controlled, Open-label Study to Evaluate the Patient Retention of Fingolimod vs. Approved First-line Disease Modifying Therapies in Adults With Relapsing Remitting Multiple Sclerosis (PREFERMS)
Status: Enrolling
Updated:  12/14/2017
Novartis Investigative Site
mi
from
Phoenix, AZ
Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease Modifying Therapy in Patients With Relapsing Remitting Multiple Sclerosis.
A 12-month, Prospective, Randomized, Active-controlled, Open-label Study to Evaluate the Patient Retention of Fingolimod vs. Approved First-line Disease Modifying Therapies in Adults With Relapsing Remitting Multiple Sclerosis (PREFERMS)
Status: Enrolling
Updated: 12/14/2017
Novartis Investigative Site
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease Modifying Therapy in Patients With Relapsing Remitting Multiple Sclerosis.
A 12-month, Prospective, Randomized, Active-controlled, Open-label Study to Evaluate the Patient Retention of Fingolimod vs. Approved First-line Disease Modifying Therapies in Adults With Relapsing Remitting Multiple Sclerosis (PREFERMS)
Status: Enrolling
Updated:  12/14/2017
Novartis Investigative Site
mi
from
Phoenix, AZ
Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease Modifying Therapy in Patients With Relapsing Remitting Multiple Sclerosis.
A 12-month, Prospective, Randomized, Active-controlled, Open-label Study to Evaluate the Patient Retention of Fingolimod vs. Approved First-line Disease Modifying Therapies in Adults With Relapsing Remitting Multiple Sclerosis (PREFERMS)
Status: Enrolling
Updated: 12/14/2017
Novartis Investigative Site
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease Modifying Therapy in Patients With Relapsing Remitting Multiple Sclerosis.
A 12-month, Prospective, Randomized, Active-controlled, Open-label Study to Evaluate the Patient Retention of Fingolimod vs. Approved First-line Disease Modifying Therapies in Adults With Relapsing Remitting Multiple Sclerosis (PREFERMS)
Status: Enrolling
Updated:  12/14/2017
Novartis Investigative Site
mi
from
Sun City, AZ
Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease Modifying Therapy in Patients With Relapsing Remitting Multiple Sclerosis.
A 12-month, Prospective, Randomized, Active-controlled, Open-label Study to Evaluate the Patient Retention of Fingolimod vs. Approved First-line Disease Modifying Therapies in Adults With Relapsing Remitting Multiple Sclerosis (PREFERMS)
Status: Enrolling
Updated: 12/14/2017
Novartis Investigative Site
mi
from
Sun City, AZ
Click here to add this to my saved trials
Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease Modifying Therapy in Patients With Relapsing Remitting Multiple Sclerosis.
A 12-month, Prospective, Randomized, Active-controlled, Open-label Study to Evaluate the Patient Retention of Fingolimod vs. Approved First-line Disease Modifying Therapies in Adults With Relapsing Remitting Multiple Sclerosis (PREFERMS)
Status: Enrolling
Updated:  12/14/2017
Novartis Investigative Site
mi
from
Tucson, AZ
Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease Modifying Therapy in Patients With Relapsing Remitting Multiple Sclerosis.
A 12-month, Prospective, Randomized, Active-controlled, Open-label Study to Evaluate the Patient Retention of Fingolimod vs. Approved First-line Disease Modifying Therapies in Adults With Relapsing Remitting Multiple Sclerosis (PREFERMS)
Status: Enrolling
Updated: 12/14/2017
Novartis Investigative Site
mi
from
Tucson, AZ
Click here to add this to my saved trials
Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease Modifying Therapy in Patients With Relapsing Remitting Multiple Sclerosis.
A 12-month, Prospective, Randomized, Active-controlled, Open-label Study to Evaluate the Patient Retention of Fingolimod vs. Approved First-line Disease Modifying Therapies in Adults With Relapsing Remitting Multiple Sclerosis (PREFERMS)
Status: Enrolling
Updated:  12/14/2017
Novartis Investigative Site
mi
from
Sherwood, AR
Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease Modifying Therapy in Patients With Relapsing Remitting Multiple Sclerosis.
A 12-month, Prospective, Randomized, Active-controlled, Open-label Study to Evaluate the Patient Retention of Fingolimod vs. Approved First-line Disease Modifying Therapies in Adults With Relapsing Remitting Multiple Sclerosis (PREFERMS)
Status: Enrolling
Updated: 12/14/2017
Novartis Investigative Site
mi
from
Sherwood, AR
Click here to add this to my saved trials
Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease Modifying Therapy in Patients With Relapsing Remitting Multiple Sclerosis.
A 12-month, Prospective, Randomized, Active-controlled, Open-label Study to Evaluate the Patient Retention of Fingolimod vs. Approved First-line Disease Modifying Therapies in Adults With Relapsing Remitting Multiple Sclerosis (PREFERMS)
Status: Enrolling
Updated:  12/14/2017
Novartis Investigative Site
mi
from
Fullerton, CA
Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease Modifying Therapy in Patients With Relapsing Remitting Multiple Sclerosis.
A 12-month, Prospective, Randomized, Active-controlled, Open-label Study to Evaluate the Patient Retention of Fingolimod vs. Approved First-line Disease Modifying Therapies in Adults With Relapsing Remitting Multiple Sclerosis (PREFERMS)
Status: Enrolling
Updated: 12/14/2017
Novartis Investigative Site
mi
from
Fullerton, CA
Click here to add this to my saved trials
Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease Modifying Therapy in Patients With Relapsing Remitting Multiple Sclerosis.
A 12-month, Prospective, Randomized, Active-controlled, Open-label Study to Evaluate the Patient Retention of Fingolimod vs. Approved First-line Disease Modifying Therapies in Adults With Relapsing Remitting Multiple Sclerosis (PREFERMS)
Status: Enrolling
Updated:  12/14/2017
Novartis Investigative Site
mi
from
Oceanside, CA
Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease Modifying Therapy in Patients With Relapsing Remitting Multiple Sclerosis.
A 12-month, Prospective, Randomized, Active-controlled, Open-label Study to Evaluate the Patient Retention of Fingolimod vs. Approved First-line Disease Modifying Therapies in Adults With Relapsing Remitting Multiple Sclerosis (PREFERMS)
Status: Enrolling
Updated: 12/14/2017
Novartis Investigative Site
mi
from
Oceanside, CA
Click here to add this to my saved trials
Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease Modifying Therapy in Patients With Relapsing Remitting Multiple Sclerosis.
A 12-month, Prospective, Randomized, Active-controlled, Open-label Study to Evaluate the Patient Retention of Fingolimod vs. Approved First-line Disease Modifying Therapies in Adults With Relapsing Remitting Multiple Sclerosis (PREFERMS)
Status: Enrolling
Updated:  12/14/2017
Novartis Investigative Site
mi
from
San Francisco, CA
Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease Modifying Therapy in Patients With Relapsing Remitting Multiple Sclerosis.
A 12-month, Prospective, Randomized, Active-controlled, Open-label Study to Evaluate the Patient Retention of Fingolimod vs. Approved First-line Disease Modifying Therapies in Adults With Relapsing Remitting Multiple Sclerosis (PREFERMS)
Status: Enrolling
Updated: 12/14/2017
Novartis Investigative Site
mi
from
San Francisco, CA
Click here to add this to my saved trials
Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease Modifying Therapy in Patients With Relapsing Remitting Multiple Sclerosis.
A 12-month, Prospective, Randomized, Active-controlled, Open-label Study to Evaluate the Patient Retention of Fingolimod vs. Approved First-line Disease Modifying Therapies in Adults With Relapsing Remitting Multiple Sclerosis (PREFERMS)
Status: Enrolling
Updated:  12/14/2017
Novartis Investigative Site
mi
from
Walnut Creek, CA
Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease Modifying Therapy in Patients With Relapsing Remitting Multiple Sclerosis.
A 12-month, Prospective, Randomized, Active-controlled, Open-label Study to Evaluate the Patient Retention of Fingolimod vs. Approved First-line Disease Modifying Therapies in Adults With Relapsing Remitting Multiple Sclerosis (PREFERMS)
Status: Enrolling
Updated: 12/14/2017
Novartis Investigative Site
mi
from
Walnut Creek, CA
Click here to add this to my saved trials
Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease Modifying Therapy in Patients With Relapsing Remitting Multiple Sclerosis.
A 12-month, Prospective, Randomized, Active-controlled, Open-label Study to Evaluate the Patient Retention of Fingolimod vs. Approved First-line Disease Modifying Therapies in Adults With Relapsing Remitting Multiple Sclerosis (PREFERMS)
Status: Enrolling
Updated:  12/14/2017
Novartis Investigative Site
mi
from
Basalt, CO
Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease Modifying Therapy in Patients With Relapsing Remitting Multiple Sclerosis.
A 12-month, Prospective, Randomized, Active-controlled, Open-label Study to Evaluate the Patient Retention of Fingolimod vs. Approved First-line Disease Modifying Therapies in Adults With Relapsing Remitting Multiple Sclerosis (PREFERMS)
Status: Enrolling
Updated: 12/14/2017
Novartis Investigative Site
mi
from
Basalt, CO
Click here to add this to my saved trials
Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease Modifying Therapy in Patients With Relapsing Remitting Multiple Sclerosis.
A 12-month, Prospective, Randomized, Active-controlled, Open-label Study to Evaluate the Patient Retention of Fingolimod vs. Approved First-line Disease Modifying Therapies in Adults With Relapsing Remitting Multiple Sclerosis (PREFERMS)
Status: Enrolling
Updated:  12/14/2017
Novartis Investigative Site
mi
from
Boulder, CO
Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease Modifying Therapy in Patients With Relapsing Remitting Multiple Sclerosis.
A 12-month, Prospective, Randomized, Active-controlled, Open-label Study to Evaluate the Patient Retention of Fingolimod vs. Approved First-line Disease Modifying Therapies in Adults With Relapsing Remitting Multiple Sclerosis (PREFERMS)
Status: Enrolling
Updated: 12/14/2017
Novartis Investigative Site
mi
from
Boulder, CO
Click here to add this to my saved trials
Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease Modifying Therapy in Patients With Relapsing Remitting Multiple Sclerosis.
A 12-month, Prospective, Randomized, Active-controlled, Open-label Study to Evaluate the Patient Retention of Fingolimod vs. Approved First-line Disease Modifying Therapies in Adults With Relapsing Remitting Multiple Sclerosis (PREFERMS)
Status: Enrolling
Updated:  12/14/2017
Novartis
mi
from
Denver, CO
Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease Modifying Therapy in Patients With Relapsing Remitting Multiple Sclerosis.
A 12-month, Prospective, Randomized, Active-controlled, Open-label Study to Evaluate the Patient Retention of Fingolimod vs. Approved First-line Disease Modifying Therapies in Adults With Relapsing Remitting Multiple Sclerosis (PREFERMS)
Status: Enrolling
Updated: 12/14/2017
Novartis
mi
from
Denver, CO
Click here to add this to my saved trials
Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease Modifying Therapy in Patients With Relapsing Remitting Multiple Sclerosis.
A 12-month, Prospective, Randomized, Active-controlled, Open-label Study to Evaluate the Patient Retention of Fingolimod vs. Approved First-line Disease Modifying Therapies in Adults With Relapsing Remitting Multiple Sclerosis (PREFERMS)
Status: Enrolling
Updated:  12/14/2017
Novartis
mi
from
Denver, CO
Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease Modifying Therapy in Patients With Relapsing Remitting Multiple Sclerosis.
A 12-month, Prospective, Randomized, Active-controlled, Open-label Study to Evaluate the Patient Retention of Fingolimod vs. Approved First-line Disease Modifying Therapies in Adults With Relapsing Remitting Multiple Sclerosis (PREFERMS)
Status: Enrolling
Updated: 12/14/2017
Novartis
mi
from
Denver, CO
Click here to add this to my saved trials
Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease Modifying Therapy in Patients With Relapsing Remitting Multiple Sclerosis.
A 12-month, Prospective, Randomized, Active-controlled, Open-label Study to Evaluate the Patient Retention of Fingolimod vs. Approved First-line Disease Modifying Therapies in Adults With Relapsing Remitting Multiple Sclerosis (PREFERMS)
Status: Enrolling
Updated:  12/14/2017
Novartis Investigative Site
mi
from
Fort Collins, CO
Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease Modifying Therapy in Patients With Relapsing Remitting Multiple Sclerosis.
A 12-month, Prospective, Randomized, Active-controlled, Open-label Study to Evaluate the Patient Retention of Fingolimod vs. Approved First-line Disease Modifying Therapies in Adults With Relapsing Remitting Multiple Sclerosis (PREFERMS)
Status: Enrolling
Updated: 12/14/2017
Novartis Investigative Site
mi
from
Fort Collins, CO
Click here to add this to my saved trials
Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease Modifying Therapy in Patients With Relapsing Remitting Multiple Sclerosis.
A 12-month, Prospective, Randomized, Active-controlled, Open-label Study to Evaluate the Patient Retention of Fingolimod vs. Approved First-line Disease Modifying Therapies in Adults With Relapsing Remitting Multiple Sclerosis (PREFERMS)
Status: Enrolling
Updated:  12/14/2017
Novartis Investigative Site
mi
from
Fort Collins, CO
Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease Modifying Therapy in Patients With Relapsing Remitting Multiple Sclerosis.
A 12-month, Prospective, Randomized, Active-controlled, Open-label Study to Evaluate the Patient Retention of Fingolimod vs. Approved First-line Disease Modifying Therapies in Adults With Relapsing Remitting Multiple Sclerosis (PREFERMS)
Status: Enrolling
Updated: 12/14/2017
Novartis Investigative Site
mi
from
Fort Collins, CO
Click here to add this to my saved trials
Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease Modifying Therapy in Patients With Relapsing Remitting Multiple Sclerosis.
A 12-month, Prospective, Randomized, Active-controlled, Open-label Study to Evaluate the Patient Retention of Fingolimod vs. Approved First-line Disease Modifying Therapies in Adults With Relapsing Remitting Multiple Sclerosis (PREFERMS)
Status: Enrolling
Updated:  12/14/2017
Novartis Investigative Site
mi
from
Fairfield, CT
Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease Modifying Therapy in Patients With Relapsing Remitting Multiple Sclerosis.
A 12-month, Prospective, Randomized, Active-controlled, Open-label Study to Evaluate the Patient Retention of Fingolimod vs. Approved First-line Disease Modifying Therapies in Adults With Relapsing Remitting Multiple Sclerosis (PREFERMS)
Status: Enrolling
Updated: 12/14/2017
Novartis Investigative Site
mi
from
Fairfield, CT
Click here to add this to my saved trials
Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease Modifying Therapy in Patients With Relapsing Remitting Multiple Sclerosis.
A 12-month, Prospective, Randomized, Active-controlled, Open-label Study to Evaluate the Patient Retention of Fingolimod vs. Approved First-line Disease Modifying Therapies in Adults With Relapsing Remitting Multiple Sclerosis (PREFERMS)
Status: Enrolling
Updated:  12/14/2017
Novartis Investigative Site
mi
from
New London, CT
Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease Modifying Therapy in Patients With Relapsing Remitting Multiple Sclerosis.
A 12-month, Prospective, Randomized, Active-controlled, Open-label Study to Evaluate the Patient Retention of Fingolimod vs. Approved First-line Disease Modifying Therapies in Adults With Relapsing Remitting Multiple Sclerosis (PREFERMS)
Status: Enrolling
Updated: 12/14/2017
Novartis Investigative Site
mi
from
New London, CT
Click here to add this to my saved trials
Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease Modifying Therapy in Patients With Relapsing Remitting Multiple Sclerosis.
A 12-month, Prospective, Randomized, Active-controlled, Open-label Study to Evaluate the Patient Retention of Fingolimod vs. Approved First-line Disease Modifying Therapies in Adults With Relapsing Remitting Multiple Sclerosis (PREFERMS)
Status: Enrolling
Updated:  12/14/2017
Novartis Investigative Site
mi
from
Dover, DE
Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease Modifying Therapy in Patients With Relapsing Remitting Multiple Sclerosis.
A 12-month, Prospective, Randomized, Active-controlled, Open-label Study to Evaluate the Patient Retention of Fingolimod vs. Approved First-line Disease Modifying Therapies in Adults With Relapsing Remitting Multiple Sclerosis (PREFERMS)
Status: Enrolling
Updated: 12/14/2017
Novartis Investigative Site
mi
from
Dover, DE
Click here to add this to my saved trials
Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease Modifying Therapy in Patients With Relapsing Remitting Multiple Sclerosis.
A 12-month, Prospective, Randomized, Active-controlled, Open-label Study to Evaluate the Patient Retention of Fingolimod vs. Approved First-line Disease Modifying Therapies in Adults With Relapsing Remitting Multiple Sclerosis (PREFERMS)
Status: Enrolling
Updated:  12/14/2017
Novartis Investigative Site
mi
from
Atlantis, FL
Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease Modifying Therapy in Patients With Relapsing Remitting Multiple Sclerosis.
A 12-month, Prospective, Randomized, Active-controlled, Open-label Study to Evaluate the Patient Retention of Fingolimod vs. Approved First-line Disease Modifying Therapies in Adults With Relapsing Remitting Multiple Sclerosis (PREFERMS)
Status: Enrolling
Updated: 12/14/2017
Novartis Investigative Site
mi
from
Atlantis, FL
Click here to add this to my saved trials
Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease Modifying Therapy in Patients With Relapsing Remitting Multiple Sclerosis.
A 12-month, Prospective, Randomized, Active-controlled, Open-label Study to Evaluate the Patient Retention of Fingolimod vs. Approved First-line Disease Modifying Therapies in Adults With Relapsing Remitting Multiple Sclerosis (PREFERMS)
Status: Enrolling
Updated:  12/14/2017
Novartis Investigative Site
mi
from
Bradenton, FL
Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease Modifying Therapy in Patients With Relapsing Remitting Multiple Sclerosis.
A 12-month, Prospective, Randomized, Active-controlled, Open-label Study to Evaluate the Patient Retention of Fingolimod vs. Approved First-line Disease Modifying Therapies in Adults With Relapsing Remitting Multiple Sclerosis (PREFERMS)
Status: Enrolling
Updated: 12/14/2017
Novartis Investigative Site
mi
from
Bradenton, FL
Click here to add this to my saved trials
Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease Modifying Therapy in Patients With Relapsing Remitting Multiple Sclerosis.
A 12-month, Prospective, Randomized, Active-controlled, Open-label Study to Evaluate the Patient Retention of Fingolimod vs. Approved First-line Disease Modifying Therapies in Adults With Relapsing Remitting Multiple Sclerosis (PREFERMS)
Status: Enrolling
Updated:  12/14/2017
Novartis Investigative Site
mi
from
Delray Beach, FL
Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease Modifying Therapy in Patients With Relapsing Remitting Multiple Sclerosis.
A 12-month, Prospective, Randomized, Active-controlled, Open-label Study to Evaluate the Patient Retention of Fingolimod vs. Approved First-line Disease Modifying Therapies in Adults With Relapsing Remitting Multiple Sclerosis (PREFERMS)
Status: Enrolling
Updated: 12/14/2017
Novartis Investigative Site
mi
from
Delray Beach, FL
Click here to add this to my saved trials
Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease Modifying Therapy in Patients With Relapsing Remitting Multiple Sclerosis.
A 12-month, Prospective, Randomized, Active-controlled, Open-label Study to Evaluate the Patient Retention of Fingolimod vs. Approved First-line Disease Modifying Therapies in Adults With Relapsing Remitting Multiple Sclerosis (PREFERMS)
Status: Enrolling
Updated:  12/14/2017
Novartis Investigative Site
mi
from
Hollywood, FL
Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease Modifying Therapy in Patients With Relapsing Remitting Multiple Sclerosis.
A 12-month, Prospective, Randomized, Active-controlled, Open-label Study to Evaluate the Patient Retention of Fingolimod vs. Approved First-line Disease Modifying Therapies in Adults With Relapsing Remitting Multiple Sclerosis (PREFERMS)
Status: Enrolling
Updated: 12/14/2017
Novartis Investigative Site
mi
from
Hollywood, FL
Click here to add this to my saved trials
Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease Modifying Therapy in Patients With Relapsing Remitting Multiple Sclerosis.
A 12-month, Prospective, Randomized, Active-controlled, Open-label Study to Evaluate the Patient Retention of Fingolimod vs. Approved First-line Disease Modifying Therapies in Adults With Relapsing Remitting Multiple Sclerosis (PREFERMS)
Status: Enrolling
Updated:  12/14/2017
Novartis Investigative Site
mi
from
Jacksonville, FL
Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease Modifying Therapy in Patients With Relapsing Remitting Multiple Sclerosis.
A 12-month, Prospective, Randomized, Active-controlled, Open-label Study to Evaluate the Patient Retention of Fingolimod vs. Approved First-line Disease Modifying Therapies in Adults With Relapsing Remitting Multiple Sclerosis (PREFERMS)
Status: Enrolling
Updated: 12/14/2017
Novartis Investigative Site
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease Modifying Therapy in Patients With Relapsing Remitting Multiple Sclerosis.
A 12-month, Prospective, Randomized, Active-controlled, Open-label Study to Evaluate the Patient Retention of Fingolimod vs. Approved First-line Disease Modifying Therapies in Adults With Relapsing Remitting Multiple Sclerosis (PREFERMS)
Status: Enrolling
Updated:  12/14/2017
Novartis Investigative Site
mi
from
Jacksonville, FL
Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease Modifying Therapy in Patients With Relapsing Remitting Multiple Sclerosis.
A 12-month, Prospective, Randomized, Active-controlled, Open-label Study to Evaluate the Patient Retention of Fingolimod vs. Approved First-line Disease Modifying Therapies in Adults With Relapsing Remitting Multiple Sclerosis (PREFERMS)
Status: Enrolling
Updated: 12/14/2017
Novartis Investigative Site
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease Modifying Therapy in Patients With Relapsing Remitting Multiple Sclerosis.
A 12-month, Prospective, Randomized, Active-controlled, Open-label Study to Evaluate the Patient Retention of Fingolimod vs. Approved First-line Disease Modifying Therapies in Adults With Relapsing Remitting Multiple Sclerosis (PREFERMS)
Status: Enrolling
Updated:  12/14/2017
Novartis Investigative Site
mi
from
North Palm Beach, FL
Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease Modifying Therapy in Patients With Relapsing Remitting Multiple Sclerosis.
A 12-month, Prospective, Randomized, Active-controlled, Open-label Study to Evaluate the Patient Retention of Fingolimod vs. Approved First-line Disease Modifying Therapies in Adults With Relapsing Remitting Multiple Sclerosis (PREFERMS)
Status: Enrolling
Updated: 12/14/2017
Novartis Investigative Site
mi
from
North Palm Beach, FL
Click here to add this to my saved trials
Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease Modifying Therapy in Patients With Relapsing Remitting Multiple Sclerosis.
A 12-month, Prospective, Randomized, Active-controlled, Open-label Study to Evaluate the Patient Retention of Fingolimod vs. Approved First-line Disease Modifying Therapies in Adults With Relapsing Remitting Multiple Sclerosis (PREFERMS)
Status: Enrolling
Updated:  12/14/2017
Novartis Investigative Site
mi
from
Plantation, FL
Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease Modifying Therapy in Patients With Relapsing Remitting Multiple Sclerosis.
A 12-month, Prospective, Randomized, Active-controlled, Open-label Study to Evaluate the Patient Retention of Fingolimod vs. Approved First-line Disease Modifying Therapies in Adults With Relapsing Remitting Multiple Sclerosis (PREFERMS)
Status: Enrolling
Updated: 12/14/2017
Novartis Investigative Site
mi
from
Plantation, FL
Click here to add this to my saved trials
Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease Modifying Therapy in Patients With Relapsing Remitting Multiple Sclerosis.
A 12-month, Prospective, Randomized, Active-controlled, Open-label Study to Evaluate the Patient Retention of Fingolimod vs. Approved First-line Disease Modifying Therapies in Adults With Relapsing Remitting Multiple Sclerosis (PREFERMS)
Status: Enrolling
Updated:  12/14/2017
Novartis Investigative Site
mi
from
Pompano Beach, FL
Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease Modifying Therapy in Patients With Relapsing Remitting Multiple Sclerosis.
A 12-month, Prospective, Randomized, Active-controlled, Open-label Study to Evaluate the Patient Retention of Fingolimod vs. Approved First-line Disease Modifying Therapies in Adults With Relapsing Remitting Multiple Sclerosis (PREFERMS)
Status: Enrolling
Updated: 12/14/2017
Novartis Investigative Site
mi
from
Pompano Beach, FL
Click here to add this to my saved trials
Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease Modifying Therapy in Patients With Relapsing Remitting Multiple Sclerosis.
A 12-month, Prospective, Randomized, Active-controlled, Open-label Study to Evaluate the Patient Retention of Fingolimod vs. Approved First-line Disease Modifying Therapies in Adults With Relapsing Remitting Multiple Sclerosis (PREFERMS)
Status: Enrolling
Updated:  12/14/2017
Novartis Investigative Site
mi
from
Port Orange, FL
Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease Modifying Therapy in Patients With Relapsing Remitting Multiple Sclerosis.
A 12-month, Prospective, Randomized, Active-controlled, Open-label Study to Evaluate the Patient Retention of Fingolimod vs. Approved First-line Disease Modifying Therapies in Adults With Relapsing Remitting Multiple Sclerosis (PREFERMS)
Status: Enrolling
Updated: 12/14/2017
Novartis Investigative Site
mi
from
Port Orange, FL
Click here to add this to my saved trials